Business expenses have been on the rise at the company in the fourth quarter of 2022

As the earnings season of the October to December 31 2022 resumes, the most corporations have declared the respective results. Some of them, have been several businesses in the Major Pharmaceutical Preparations sector. And now, Pyxis Oncology Inc issued operating deficit of $-37.973 millions, for the fourth quarter of 2022.

The smartest approach to frame the fourth quarter of 2022 development, at the prevailing stage of the company. It is simple to correlate the operating profit of the fourth quarter of 2021, which has been $11.621 millions.


Regardless if the income in the ongoing situation of the company has, the subordinate role. On the other hand, it is crucial to indicate, that the PYXS has experienced a shortfall of $-36.101 millions, in the fourth quarter of 2022, meanwhile it was profitable in the fourth quarter of 2021.

What's more important, the PYXS pointed out as well a shortfall of $-120.72 millions and for the fiscal 12 Months 2022, Revenues of $0.00 millions.

Major Pharmaceutical Preparations The Major Pharmaceutical Preparations company has decreased it's shortfall per share to $-3.65 from $-8.95 in the prior fiscal year, while by 0 % from $0.00 millions a year before.

Pyxis Oncology Inc is expected to report next financial results on May 12, 2023.

Pyxis Oncology Inc's Inventory Turnover Ratio

Pyxis Oncology Inc's Price to Cash Flow ratio

Other PYXS's Earnings Reports

The evolving business from the Major Pharmaceutical Preparations market the PYXS reported the financial span ending second quarter of 2022, numbers